Make your own free website on Tripod.com

cancerTrials logo

News and Features

home

 

search

 

contact

 

Early Endostatin Results Show Promise

(November 6, 2000) — Several drugs designed to cut off a tumor’s blood supply, including the widely publicized Endostatin, are showing promise in early (phase I) clinical trials, according to reports from a meeting on new cancer drugs taking place this week in Amsterdam. Speakers at the Symposium on New Drugs in Cancer Therapy are reporting on seven different anti-angiogenesis drugs.

Angiogenesis (blood vessel growth) inhibitors are one of the new kinds of biological cancer therapies targeting the underlying mechanisms that allow a cell or tumor to grow. The seven drugs discussed at the Amsterdam meeting are among at least 17 anti-angiogenesis agents now in clinical trials.

While the seven angiogenesis inhibitors discussed at the meeting have still to be tested in much larger groups of patients, the early results "have clearly shown their potential as anticancer agents for the future," the symposium organizers said in a statement.

Endostatin received media attention in1998 with the news that it successfully reversed tumors in laboratory mice, and again in fall 1999 when the first phase I trials began. Those trials, two of which are sponsored by the National Cancer Institute (NCI), are now nearing completion.

When these initial trials are finished, NCI will review the complete data in concert with the investigators and EntreMed, the drug company sponsor. Decisions regarding Phase II development will be made at that time – possibly early in 2001.

The 11th Symposium on New Drugs in Cancer Therapy, sponsored by the NCI, the European Organization for Research and Treatment of Cancer, and the American Association for Cancer Research (AACR) is taking place November 7-11, 2000, in Amsterdam. Abstracts from the Amsterdam meeting will appear on the AACR Web site with reports on the following drugs:

  • Angiostatin (EntreMed), abstracts 046, 261
  • Endostatin (EntreMed), abstracts 258-260, 577, 578
  • SU5416 (Sugen), abstracts 262-265, 275, 375, 580
  • SU6668 (Sugen), abstracts 265, 266, 581
  • AngiozymeTM (Ribozyme Pharmaceuticals), abstract 267
  • Cilengitide (E. Merck), abstract 296
  • HuMV833 (PDL), abstracts 270, 579

date posted 11/06/00

 

Related Pages

Anti-angiogenesis Index

Anti-angiogenesis Information on CancerNet


Understanding || Types of Cancer || Finding || News || Researchers

Search || Beyond cancerTrials || About || Contact Us

NCI Home Page